Home
Conferences
All Conferences
ESMO 2026
GBCC 2026
SABCS 2025
GBCC 2025
SABCS 2024
SABCS 2023
Add Your Conference
Register
Log in
2026 Video Highlights - Begins May 6th
Supported by An Educational Grant From Stemline/Menarini
Tentative Schedule of Programming
View Session
4092642
ESMO 2026: 415O – 1L Dato-DXd vs chemotherapy in locally recurrent/metastatic TNBC (immunotherapy-ineligible): PROs from TROPION-Breast02
5:00 Minutes
1:00 PM-
View Session
4092602
ESMO 2026: 1O - ctDNA detection rates during surveillance in high-risk HR+/HER2 negative breast cancer from the TRAK-ER study
5:00 Minutes
1:00 PM-
View Session
4092604
ESMO 2026: LBA2 - A window-of-opportunity (WOO) trial of giredestrant +/- LHRH analogue vs anastrozole + LHRHa in premenopausal patientswith ER+/HER2- early breast cancer: PREcoopERA
5:00 Minutes
1:00 PM-
View Session
4092595
ESMO 2026: 215O – Atezolizumab + Capecitabine vs Capecitabine Alone in Residual TNBC: The MIRINAE Trial
5:00 Minutes
1:00 PM-
View Session
4092592
ESMO 2026: 214O - Chemotherapy-free, pathological complete response (pCR)-guided strategy with trastuzumab-pertuzumab (HP) and T-DM1 inHER2+ early breast cancer (EBC): PHERGain-2
5:00 Minutes
1:00 PM-
View Session
4092657
ESMO 2026: 416O - SMART: On-treatment ctDNA dynamics predicts response and progression in metastatic breast cancer
5:00 Minutes
1:00 PM-
View Session
4092606
ESMO 2026: 418O – Safety & PROs from evERA BC: Phase III trial of giredestrant + everolimus in ER+/HER2− advanced BC after prior CDK4/6i
5:00 Minutes
1:00 PM-
View Session
4092587
ESMO 2026: LBA1 – T-DXd vs ddAC-THP: Residual Cancer Burden in High-Risk HER2+ Early Breast Cancer
5:00 Minutes
1:00 PM-
View Session
4092659
ESMO 2026: 417O - Capivasertib (C) and fulvestrant (F) for patients (pts) with HR+/HER2_ advanced breast cancer (ABC): final overall survival(OS) results from the Phase 3 CAPItello-291 trial
5:00 Minutes
1:00 PM-
© 2025 Encore Medical Education. All Rights Reserved.
Terms & Conditions
Privacy Policy
Copy to Clipboard
